ReviewInternational ophthalmology2019
Ocular sebaceous gland carcinoma: an update of the literature.
Review in International ophthalmology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 59 citations in OpenAlex.
- Identification of an efficient immunohistochemical panel for precise differential diagnosis of sebaceous carcinoma of eyelid.Discover oncology · 2025Article
- Proteomics reveals the regulation of ALG1 expression by lentivirus-mediated THBS1 overexpression and its mechanism in meibomian gland carcinoma.Oncology letters · 2025Article
- Clinical Outcomes and Prognostic Factors in Eyelid Malignancy: A 17-Year Retrospective Analysis of Surgical Management and Reconstruction Techniques.Korean journal of ophthalmology : KJO · 2025Article
- Clinicopathologic Features of Eyelid Sebaceous Gland Carcinoma Requiring Immunohistochemical Diagnosis.Ocular oncology and pathology · 2024Article
- Diagnosis and treatment of malignant eyelid tumors.Die Ophthalmologie · 2024Review
- Case report: A rare case of oral sebaceous carcinoma in the upper lip.Pathology oncology research : POR · 2024Article
- Sebaceous carcinoma: an updated review of pathogenesis, diagnosis, and treatment options.Archives of dermatological research · 2023Review
- A Rare Manifestation of Discoid Lupus Erythematosus Solely in the Lower Eyelid of a Young Man.Cureus · 2023Article
- Development and validation of a nomogram to predict the recurrence of eyelid sebaceous gland carcinoma.Cancer medicine · 2023Article
- Sebaceous Neoplasms.Diagnostics (Basel, Switzerland) · 2023Review
- Malignant lesions of the caruncle.Eye (London, England) · 2023Review
- [Diagnosis and treatment of malignant eyelid tumors].Die Ophthalmologie · 2023Review
- Primary Sebaceous Carcinoma of the Eyebrow: A Case Report.Clinical, cosmetic and investigational dermatology · 2023Article
- Primary or metastatic lung cancer? Sebaceous carcinoma of the thigh: A case report.World journal of clinical cases · 2022Article
- Overexpression of miR-651-5p inhibits ultraviolet radiation-induced malignant biological behaviors of sebaceous gland carcinoma cells by targetingAnnals of translational medicine · 2022Article
- Outcome after treatment for sebaceous carcinoma: A multicenter study.Journal of surgical oncology · 2022Article
- The effect of direct cell injury inflicted by cryotherapy on eyelid sebaceous gland carcinoma cells: An ex-vivo experimental study.Indian journal of ophthalmology · 2022Article
- MicroRNA-3907 promotes the proliferation and migration of sebaceous gland carcinoma of the eyelid by targeting thrombospondin 1.Oncology letters · 2021Article
- Sebaceous Gland Carcinoma with Misleading Clinical Appearance: A Case Report of an Eyelid Lesion.The American journal of case reports · 2020Article
- A case of repeat resection for recurrent pulmonary metastasis from sebaceous gland carcinoma.Surgical case reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo review and summarize the newest update on ocular sebaceous gland carcinoma (SGC) focusing on diagnosis and treatment.
methodsA PubMed search was carried out using the terms "Sebaceous Carcinoma", "Meibomian Gland Carcinoma", "Sebaceous Cell Carcinoma", and "Sebaceous Gland Carcinoma". All studies published in English up to October 2017 were included in this review.
resultsGlobally, the overall incidence of SGC is increasing making it the third most common eyelid malignancy after basal cell carcinoma (BCC) and squamous cell carcinoma. The mainstay of treatment of ocular SGC is wide surgical resection under frozen section or Moh's micrographic surgery control followed by eyelid reconstruction. Based on histopathological features, SGC can be classified according to growth pattern, cell type, and cytoarchitecture. Based on the growth pattern, they can be classified as trabecular, lobular, papillary, and BCC-like. The cell type can be classified as basaloid, basosquamous, and epidermoid. The SGC cytoarchitecture presents either as a nodular or as an infiltrative lesion. Based on immunohistochemistry, the overexpression of ZEB2, BAG3, androgen receptor, and C-erbB-2 oncoprotein is associated with poor prognosis. The tumor is associated with systemic metastasis in 8-14% and death in 10-30%.
conclusionOcular SGC is an aggressive tumor associated with poor prognosis. Early identification and appropriate treatment may help improve the prognosis. New insight into its pathogenesis and the immunohistochemical profile may lead to the development of new effective treatment strategies, along with traditional therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.